Comparative Pharmacology
Head-to-head clinical analysis: HALOTESTIN versus TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOTESTIN versus TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE.
HALOTESTIN vs TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluoxymesterone is a synthetic androgen that binds to androgen receptors, activating gene transcription and promoting protein synthesis, leading to anabolic and androgenic effects.
Testosterone enanthate is a prodrug of testosterone, which binds to androgen receptors, activating gene transcription that leads to development of male secondary sex characteristics and anabolic effects. Estradiol valerate is a prodrug of estradiol, which binds to estrogen receptors, promoting growth and development of female reproductive tissues and secondary sex characteristics.
10-20 mg orally three to four times daily for replacement therapy; 2-10 mg orally daily for delayed puberty in males.
1 to 2 mL of a combination product containing 90 mg testosterone enanthate and 4 mg estradiol valerate per mL intramuscularly every 4 weeks.
None Documented
None Documented
Terminal elimination half-life: 9.6 hours. Clinical context: Steady-state achieved after ~48 hours.
Testosterone enanthate: 4-5 days (IM). Estradiol valerate: 2-3 days (IM). Steady-state reached in ~2-3 weeks.
Renal: 90% as glucuronide and sulfate conjugates; fecal: 10%.
Testosterone enanthate and estradiol valerate are metabolized in the liver. Testosterone metabolites (e.g., androsterone, etiocholanolone) are conjugated and excreted renally (90%) and fecally (~10%). Estradiol valerate is hydrolyzed to estradiol, metabolized to estrone and estriol, conjugated, and excreted primarily renally (70-80%) with ~20% biliary/fecal.
Category C
Category D/X
Androgen
Androgen